Imeik Technology Development Co Ltd
SZSE:300896

Watchlist Manager
Imeik Technology Development Co Ltd Logo
Imeik Technology Development Co Ltd
SZSE:300896
Watchlist
Price: 171.98 CNY 0.37% Market Closed
Market Cap: 52.1B CNY
Have any thoughts about
Imeik Technology Development Co Ltd?
Write Note
Section:
 

Relative Value

The Relative Value of one Imeik Technology Development Co Ltd stock under the Base Case scenario is 258.03 CNY. Compared to the current market price of 171.98 CNY, Imeik Technology Development Co Ltd is Undervalued by 33%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Relative Value
Base Case
258.03 CNY
Undervaluation 33%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

18.1
P/S
P/S
Price to Sales
18.1
vs History
86
vs Industry
32
Median 3Y
27.8
Median 5Y
38.6
Industry
7.3
Forward
15.4
More Details
27.8
P/E
P/E
Price to Earnings
27.8
vs History
86
vs Industry
6
Median 3Y
42.5
Median 5Y
59.3
Industry
23.3
Forward
23.6
More Details
30.2
P/OCF
P/OCF
Price to OCF
30.2
vs History
73
vs Industry
10
Median 3Y
35
Median 5Y
50.2
Industry
19.8
More Details
35.1
P/FCFE
P/FCFE
Price to FCFE
35.1
vs History
68
vs Industry
9
Median 3Y
37.4
Median 5Y
57
Industry
22.6
More Details
6.7
P/B
P/B
Price to Book Value
6.7
vs History
88
vs Industry
12
Median 3Y
9.6
Median 5Y
11.1
Industry
2.7
More Details
16.4
EV/S
EV/S
Enterprise Value to Sales
16.4
vs History
86
vs Industry
28
Median 3Y
26
Median 5Y
36.7
Industry
7.6
Forward
14
More Details
17.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
17.5
vs History
86
vs Industry
28
Median 3Y
27.5
Median 5Y
39
Industry
9.4
More Details
23.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
23.3
vs History
85
vs Industry
6
Median 3Y
36.6
Median 5Y
51.4
Industry
4.7
Forward
19.1
More Details
23.3
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
23.3
vs History
85
vs Industry
6
Median 3Y
36.6
Median 5Y
51.4
Industry
4.8
Forward
20
More Details
27.5
EV/OCF
EV/OCF
Enterprise Value to OCF
27.5
vs History
73
vs Industry
10
Median 3Y
33
Median 5Y
47.5
Industry
5.3
More Details
32
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
32
vs History
68
vs Industry
8
Median 3Y
34.3
Median 5Y
53.9
Industry
3.8
More Details
13.4
EV/IC
EV/IC
Enterprise Value to IC
13.4
vs History
90
vs Industry
16
Median 3Y
19.7
Median 5Y
30.6
Industry
5
More Details

Multiples Across Competitors

Competitors Multiples
Imeik Technology Development Co Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
Imeik Technology Development Co Ltd
SZSE:300896
52B CNY 18.1 27.8 23.3 23.3
FR
Pharnext SCA
OTC:PNEXF
6T USD 33 841 650.5 -160 844.3 -195 316.3 -193 087.6
US
Abbvie Inc
NYSE:ABBV
336.7B USD 5.9 81 15.4 22.8
US
Amgen Inc
NASDAQ:AMGN
159.4B USD 4.7 26.9 14.4 23.8
US
Gilead Sciences Inc
NASDAQ:GILD
141B USD 4.9 23.6 10.3 14.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
123.1B USD 11.1 -124.5 26.5 27.8
US
Epizyme Inc
F:EPE
94.1B EUR 2 081.7 -531.2 -578.4 -563
AU
CSL Ltd
ASX:CSL
117B AUD 5 27.8 17.2 21.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
59.8B USD 4.2 13.3 11.9 13.3
US
Seagen Inc
F:SGT
39.3B EUR 20.1 -61.5 -66.3 -59.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
41.8B USD 17.8 -155 -695.4 -348.5
P/E Multiple
Earnings Growth PEG
CN
Imeik Technology Development Co Ltd
SZSE:300896
Average P/E: 33.4
27.8
14%
2
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -160 844.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
81
88%
0.9
US
Amgen Inc
NASDAQ:AMGN
26.9
45%
0.6
US
Gilead Sciences Inc
NASDAQ:GILD
23.6
188%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -124.5 N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -531.2 N/A N/A
AU
CSL Ltd
ASX:CSL
27.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
7%
1.9
US
S
Seagen Inc
F:SGT
Negative Multiple: -61.5 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -155 N/A N/A
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
Imeik Technology Development Co Ltd
SZSE:300896
Average EV/EBITDA: 17
23.3
14%
1.7
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -195 316.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
13%
1.2
US
Amgen Inc
NASDAQ:AMGN
14.4
17%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
6%
1.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.5
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -578.4 N/A N/A
AU
CSL Ltd
ASX:CSL
17.2
11%
1.6
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
11.9
11%
1.1
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.3 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -695.4 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
Imeik Technology Development Co Ltd
SZSE:300896
Average EV/EBIT: 20.9
23.3
11%
2.1
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -193 087.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.8
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
23.8
32%
0.7
US
Gilead Sciences Inc
NASDAQ:GILD
14.1
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.8
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563 N/A N/A
AU
CSL Ltd
ASX:CSL
21.5
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.3
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.8 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -348.5 N/A N/A

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 266,700+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.